[1]Ministry of Health of the People’s Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].Chin Clin Oncol, 2011, 16 (10) :929-946. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肿瘤学杂志, 2011, 16 (10) :929-946.
|
[2]HAN K, KIM JH, YOON HM, et al.Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma:clinical safety and efficacy and factors influencing patient survival[J].Korean J Radiol, 2014, 15 (4) :464-471.
|
[3]CHEN SG, ZHAO HT, ZHANG N, et al.A TACE oriented comprehensive therapy for unresectable primary liver cancer[J].Cancer Res Prevent Treat, 2005, 32 (8) :505-506. (in Chinese) 陈曙光, 赵海涛, 张宁, 等.以TACE为主综合治疗不能手术切除的原发性肝癌[J].肿瘤防治研究, 2005, 32 (8) :505-506.
|
[4]WANG MQ, TANG WJ, LIN HY, et al.Clinical implications of bile duct injury after transcatheter arterial chemoembolization[J].J Intervent Radiol, 2005, 14 (5) :493-497. (in Chinese) 王茂强, 唐文捷, 林汉英, 等.经导管肝动脉化疗栓塞术后胆管损伤的临床意义[J].介入放射学杂志, 2005, 14 (5) :493-497.
|
[5]ZHANG BH, JIANG XQ, LUO XJ, et al.Selection and evaluation on liver transplantation in end-stage of disease of biliary system[J].Oncol Progr, 2005, 3 (5) :423-425. (in Chinese) 张柏和, 姜小清, 罗祥基, 等.胆系疾病终末期行肝移植的适应证选择及评价[J].癌症进展, 2005, 3 (5) :423-425.
|